Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
PLoS One
2018 Oct 04;1310:e0205109. doi: 10.1371/journal.pone.0205109.
Show Gene links
Show Anatomy links
Functional analysis of a triplet deletion in the gene encoding the sodium glucose transporter 3, a potential risk factor for ADHD.
Schäfer N
,
Friedrich M
,
Jørgensen ME
,
Kollert S
,
Koepsell H
,
Wischmeyer E
,
Lesch KP
,
Geiger D
,
Döring F
.
???displayArticle.abstract???
Sodium-glucose transporters (SGLT) belong to the solute carrier 5 family, which is characterized by sodium dependent transport of sugars and other solutes. In contrast, the human SGLT3 (hSGLT3) isoform, encoded by SLC5A4, acts as a glucose sensor that does not transport sugar but induces membrane depolarization by Na+ currents upon ligand binding. Whole-exome sequencing (WES) of several extended pedigrees with high density of attention-deficit/hyperactivity disorder (ADHD) identified a triplet ATG deletion in SLC5A4 leading to a single amino acid loss (ΔM500) in the hSGLT3 protein imperfectly co-segregating with the clinical phenotype of ADHD. Since mutations in homologous domains of hSGLT1 and hSGLT2 were found to affect intestinal and renal function, respectively, we analyzed the functional properties of hSGLT3[wt] and [ΔM500] by voltage clamp and current clamp recordings from cRNA-injected Xenopus laevis oocytes. The cation conductance of hSGLT3[wt] was activated by application of glucose or the specific agonist 1-desoxynojirimycin (DNJ) as revealed by inward currents in the voltage clamp configuration and cell depolarization in the current clamp mode. Almost no currents and changes in membrane potential were observed when glucose or DNJ were applied to hSGLT3[ΔM500]-injected oocytes, demonstrating a loss of function by this amino acid deletion in hSGLT3. To monitor membrane targeting of wt and mutant hSGLT3, fusion constructs with YFP were generated, heterologously expressed in Xenopus laevis oocytes and analyzed for membrane fluorescence by confocal microscopy. In comparison to hSGLT3[wt] the fluorescent signal of mutant [ΔM500] was reduced by 43% indicating that the mutant phenotype might mainly result from inaccurate membrane targeting. As revealed by homology modeling, residue M500 is located in TM11 suggesting that in addition to the core structure (TM1-TM10) of the transporter, the surrounding TMs are equally crucial for transport/sensor function. In conclusion, our findings indicate that the deletion [ΔM500] in hSGLT3 inhibits membrane targeting and thus largely disrupts glucose-induced sodium conductance, which may, in interaction with other ADHD risk-related gene variants, influence the risk for ADHD in deletion carriers.
???displayArticle.pubmedLink???
30286162
???displayArticle.pmcLink???PMC6171906 ???displayArticle.link???PLoS One
Fig 1. WES screening identified a mutation in the glucose sensor SGLT3 in ADHD patients.
(A) Pedigree of family P14 with a heterozygous triplet ATG deletion in SLC5A4 leading to a single amino acid loss in SGLT3 (ÎM500), imperfectly co-segregating with the clinical phenotype of ADHD. Shading of squares (male) and circles (female) indicate affected (black) and healthy (white) family members with the SLCLC5A4 genotype carriers indicated below. (B) Representative Sanger sequencing of homozygous (upper panel) and heterozygous (lower panel) genotypes demonstrate a deletion of three nucleotides (c.1498-1500delATG) in heterozygous individuals (asterisk) resulting in a deletion of methionine 500 in the SGLT3 protein. Numbering refers to nucleotides of the open reading frame derived from the healthy (upper panel) and the mutated (lower panel) alleles.
Fig 2. Dependence of SGLT3 currents on external sodium and glucose concentrations.
(A) Two-electrode-voltage clamp recordings (VH = -50 mV) from Xenopus laevis oocytes injected with hSGLT3 display DNJ-induced inward currents that decrease by reduction of the external sodium concentration. Representative current traces from oocytes injected with hSGLT3 or water (control oocytes) are shown. (B) Bar graph quantifies hSGLT3 currents induced by 100mM glucose at different external sodium concentrations (n = 6 ± SD of two independent experiments). (C) Continuous recordings from oocytes expressing hSGLT3 display sodium inward currents that increase in amplitude by elevating the external concentration of D-glucose as indicated (VH = -50 mV; [Na+]e = 30 mM; pH 5). (D) Dose-response curve of hSGLT3 currents activated by different glucose concentrations as recorded in panel C. Data were fitted with Michaelis-Menten equation resulting in a K0.5-value of 6.0±0.9 mM (n = 6 ± SD of two independent experiments).
Fig 3. Loss of function by deletion of M500/I501 in hSGLT3 and hSGLT1.
(A and B) Xenopus laevis oocytes injected with cRNA of hSGLT3[wt], hSGLT3[ÎM500] and hSGLT3[ÎI501] were recorded in the voltage clamp mode (VC, panel A) and in the current clamp mode (CC, panel B). Representative continuous recordings at a holding potential of â50 mV, 30 mM Na+ and pH 5 from oocytes expressing hSGLT3[wt] display sodium currents in response to D-glucose (75 mM) and Deoxynojirimycin (DNJ; 10μM). Currents were blocked by the specific inhibitor Phlorizin (Pz; 240 μM). Current clamp recordings of the same oocyte reveal D-glucose- and DNJ-induced depolarization as well as phlorizin-induced hyperpolarization of the cell. Using identical conditions, no current or voltage responses were observed in oocytes expressing hSGLT3[ÎM500] or hSGLT3[ÎI501]. (C) Oocytes injected with cRNA of hSGLT1[wt], hSGLT1[ÎM500] and hSGLT1[ÎI501] were measured in the absence and presence of 100 mM glucose (pH 5, 30 mM Na+ and a membrane potential of -50 mV). Oocytes expressing hSGLT1[wt] display sodium currents in response to glucose, whereas no responses were observed in oocytes expressing hSGLT1[ÎM500] or hSGLT1[ÎI501]. (D) Left panel: bar graph quantifies current amplitudes in response to either D-glucose (75 mM) or DNJ (10 μM) at -50 mV and 30 mM Na+. As a negative control, results from H2O-injected oocytes are displayed (n = 6 ± SD of two independent experiments). Right panel: bar graph quantifies current amplitudes in response to D-glucose (100 mM) at -50 mV and 30 mM Na+ of hSGLT1[wt], hSGLT1[ÎM500] and hSGLT1[ÎI501] and water controls (n = 6 ± SD of two independent experiments).
Fig 4. Targeting of hSGLT3 and hSGLT1 to the plasma membrane is impaired by deletion of M500 or I501.
(A) Crude membrane fractions of Xenopus laevis oocytes injected with cRNA of wildtype and mutated hSGLTs or H2O (control) were analyzed by western immunoblotting. As revealed by specific hSGLT3 and hSGLT1 antibodies, signals of wildtype and mutant injected oocytes were almost identical with no specific signal in water-injected oocytes. A single protein band present in samples and control (αSGLT1) are due to cross-reactivity of the antibody (compare S3 Fig). Loading of identical amounts of protein was controlled by detection of endogenous actin with the appropriate antibody (one representative experiment out of 2 independent experiments is shown). (B) Representative confocal laser scanning images of Xenopus laevis oocytes injected with YFP-tagged hSGLT constructs are shown. Membrane fluorescences of the mutated hSGLT1 and hSGLT3 are substantially lower as compared to wildtype. (C) Bar graphs show the fluorescence intensity of the mutants hSGLT[ÎM500] or hSGLT[ÎI501] as proportion of the respective wt fluorescence (n = 6 ± SD of two independent experiments, * indicate p < 0.01; ** indicate p < 0.001).
Fig 5. A structural perspective of the ÎM500 deletion found in hSGLT3.
(A and B) Homology model of hSGLT3 that show the localization of mutated residues M500 (orange sphere), E457 (yellow sphere), R503 (pink sphere) and R499 (green sphere) and residues involved in Na+ (blue spheres) and sugar binding (black spheres) from a side (A) and top (B) perspective. Core TM helices 1â10 are shown in transparent silver whereas the surrounding helices are red and loop regions not supported by the model template are shown as silver strings. The modelled hSGLT3 carrier cavity/vestibule is shown in blue as a mesh structure.
S1 Fig. PCR analysis of human brain tissues.
Bar graph shows normalized expression of SGLT3 in diverse human brain tissues as indicated. Data are presented in arbitrary units as mean ± S.E. from three individual runs of quantitative real-time PCR. General presence of hSGLT3 in the same human samples was monitored by endpoint PCR as documented by the expected 344 bp fragment in the agarose gel of the inset. Cb Cerebellum, Cx Cortex, Hi Hippocampus, Hy Hypothalamus, Je Jejunum, Mo Medulla oblongata, Nc Nucleus caudates, Pn Pons, Pu Putamen.
S2 Fig. hSGLT3/hSGLT1 deletion mutants have no dominant negative effect on the respective SGLT wildtype transport function.
Oocytes (co-)expressing the indicated constructs were measured at -50 mV in the presence of 100 mM glucose (pH 5.0). The mean of glucose-induced steady state currents from n ⥠15 oocytes from 3 independent oocyte batches are shown.
S3 FIG. Western immunoblots of membranes from oocyte injected with transcripts of hSGLT3 and hSGLT1.
Identical uncropped blots of Fig 4A are presented. Crude membrane fractions of Xenopus laevis oocytes injected with cRNA of wildtype and mutated hSGLTs or H2O (control) were analyzed by western immunoblotting. As revealed by specific hSGLT3 and hSGLT1 antibodies signals of wildtype and mutant injected oocytes were almost identical with no signal in water-injected oocytes. Loading of identical amounts of protein was controlled by detection of endogenous actin with the appropriate antibody. Position of marker bands from blots were spotted on to x-ray films with molecular weight given on the bottom (from upper to lower). Asterisks indicate unspecific staining of SGLT1 and SGLT3 antibodies in samples and controls.
Abramson,
Structure and function of Na(+)-symporters with inverted repeats.
2009, Pubmed
Abramson,
Structure and function of Na(+)-symporters with inverted repeats.
2009,
Pubmed
Braberg,
SALIGN: a web server for alignment of multiple protein sequences and structures.
2012,
Pubmed
Calado,
Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion.
2008,
Pubmed
Carpaneto,
Phloem-localized, proton-coupled sucrose carrier ZmSUT1 mediates sucrose efflux under the control of the sucrose gradient and the proton motive force.
2005,
Pubmed
,
Xenbase
Chapman,
Whole exome sequencing in extended families with autism spectrum disorder implicates four candidate genes.
2015,
Pubmed
Chen,
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
2010,
Pubmed
Corominas,
Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome sequencing.
2020,
Pubmed
Cristino,
Neurodevelopmental and neuropsychiatric disorders represent an interconnected molecular system.
2014,
Pubmed
Dahmen,
Early pathogenic care and the development of ADHD-like symptoms.
2012,
Pubmed
de Ligt,
Diagnostic exome sequencing in persons with severe intellectual disability.
2012,
Pubmed
Diez-Sampedro,
A glucose sensor hiding in a family of transporters.
2003,
Pubmed
,
Xenbase
Díez-Sampedro,
Sugar binding residue affects apparent Na+ affinity and transport stoichiometry in mouse sodium/glucose cotransporter type 3B.
2011,
Pubmed
Díez-Sampedro,
Residue 457 controls sugar binding and transport in the Na(+)/glucose cotransporter.
2001,
Pubmed
,
Xenbase
Ehrenkranz,
Phlorizin: a review.
2005,
Pubmed
Eskandari,
Structural analysis of cloned plasma membrane proteins by freeze-fracture electron microscopy.
1998,
Pubmed
,
Xenbase
Faham,
The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport.
2008,
Pubmed
Faraone,
Molecular genetics of attention-deficit/hyperactivity disorder.
2005,
Pubmed
Faraone,
Attention-deficit/hyperactivity disorder.
2015,
Pubmed
Franke,
The genetics of attention deficit/hyperactivity disorder in adults, a review.
2012,
Pubmed
Hawi,
The molecular genetic architecture of attention deficit hyperactivity disorder.
2015,
Pubmed
Hirayama,
Sodium-dependent reorganization of the sugar-binding site of SGLT1.
2007,
Pubmed
,
Xenbase
Humphrey,
VMD: visual molecular dynamics.
1996,
Pubmed
Killeen,
A behavioral neuroenergetics theory of ADHD.
2013,
Pubmed
Klaassen,
Explaining the variable penetrance of CNVs: Parental intelligence modulates expression of intellectual impairment caused by the 22q11.2 deletion.
2016,
Pubmed
Koepsell,
The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer.
2017,
Pubmed
Krishnamurthy,
Unlocking the molecular secrets of sodium-coupled transporters.
2009,
Pubmed
Lee,
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs.
2013,
Pubmed
Lesch,
Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies.
2008,
Pubmed
Levy,
Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study.
1997,
Pubmed
Lyon,
Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implications.
2011,
Pubmed
Martín,
Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption.
1996,
Pubmed
,
Xenbase
Merker,
SLC2A3 single-nucleotide polymorphism and duplication influence cognitive processing and population-specific risk for attention-deficit/hyperactivity disorder.
2017,
Pubmed
Mueckler,
The SLC2 (GLUT) family of membrane transporters.
2013,
Pubmed
Nour-Eldin,
Advancing uracil-excision based cloning towards an ideal technique for cloning PCR fragments.
2006,
Pubmed
Ressl,
Molecular basis of transport and regulation in the Na(+)/betaine symporter BetP.
2009,
Pubmed
Romanos,
Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q13.1 and 14q12.
2008,
Pubmed
Santer,
Molecular analysis of the SGLT2 gene in patients with renal glucosuria.
2003,
Pubmed
Soták,
Putative tissue location and function of the SLC5 family member SGLT3.
2017,
Pubmed
Stühmer,
Electrophysiological recording from Xenopus oocytes.
1992,
Pubmed
,
Xenbase
Turk,
Molecular characterization of Vibrio parahaemolyticus vSGLT: a model for sodium-coupled sugar cotransporters.
2000,
Pubmed
Turk,
Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter.
1991,
Pubmed
,
Xenbase
Vandesompele,
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
2002,
Pubmed
Voss,
3V: cavity, channel and cleft volume calculator and extractor.
2010,
Pubmed
Voss,
Imino sugars are potent agonists of the human glucose sensor SGLT3.
2007,
Pubmed
,
Xenbase
Vrhovac,
Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
2015,
Pubmed
Watanabe,
The mechanism of sodium and substrate release from the binding pocket of vSGLT.
2010,
Pubmed
Webb,
Protein structure modeling with MODELLER.
2014,
Pubmed
Weyand,
Structure and molecular mechanism of a nucleobase-cation-symport-1 family transporter.
2008,
Pubmed
Wright,
Glucose transport families SLC5 and SLC50.
2013,
Pubmed
Wright,
Biology of human sodium glucose transporters.
2011,
Pubmed
Yang,
UCSF Chimera, MODELLER, and IMP: an integrated modeling system.
2012,
Pubmed
Zhou,
Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder.
2008,
Pubmed